The soluble CTLA-4 receptor: A new marker in autoimmune diseases

Archivum Immunologiae et Therapiae Experimentalis

Volumn 53, Issue 4, 2005, Pages 336-341

  Pawlak, Edyta ^a   Kochanowska, Iwona Ewa ^a   Frydecka, Irena ^a,b   Kiełbiński, Marek ^b   Potoczek, Stanisław ^b   Bilińska, Małgorzata ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Alternative splicing; Autoimmune diseases; sCTLA 4

Indexed keywords

B7 ANTIGEN; BIOCHEMICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MESSENGER RNA;

ALTERNATIVE RNA SPLICING; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; BINDING AFFINITY; CELL STIMULATION; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; EXON; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIGAND BINDING; OUTCOMES RESEARCH; REVIEW; T LYMPHOCYTE ACTIVATION;

ALTERNATIVE SPLICING; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; AUTOIMMUNE DISEASES; EXONS; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; LYMPHOPROLIFERATIVE DISORDERS; MODELS, GENETIC; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, TERTIARY; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME;

EID: 31944448797     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Amundsen S. S., Naluai A. T., Ascher H., Ek J., Gudjonsdottir A., H., Wahlström J., Lie B. A. and Sollid L. M. (2004): Genetic analysis of the CD28/CTLA4/ICOS (CELIAC 3) region in celiac disease. Tissue Antigens, 64, 593-599.
2. Azuma M., Ito D., Yagita H., Okumura K., Philips J., Lamier L. and Somoza C. (1993): B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 366, 76-79.
3. Bergholdt R., Taxvig C., Eising S., Nerup J. and Pociot F (2005): CBLB variants in type 1 diabetes and their genetic interaction with CTLA4. J. Leukoc. Biol., 77, 579-585.
4. Bocko D., Kosmaczewska A., Ciszak L., Teodorowska R. and Frydecka I. (2002): CD28 costimulatory molecule - expression, structure and function. Arch. Immunol. Ther. Exp., 50, 169-177.
5. Brunet J. F., Denizot F., Luciani M. F., Roux-Dosseto M., Suzar M. Mattei M. G. and Golstein P. (1987): A new member of the immunoglobulin superfamily - CTLA-4. Nature, 328, 267-270.
6. Carreno B. M., Bennett F., Chau T. A. Ling V., Luxenberg D., Jussif J., Baroja M. L. and Madrenas J. (2000): CTLA-4 (CD152) can inhibit T cell activation by two different mechanism depending on its level of cell surface expression. J. Immunol., 165, 1352-1356.
7. Chambers C. A., Cado D., Truong T. and Allison J. P. (1997): Thymocyte development is normal in CTLA-4-deficient mice. Proc. Natl. Acad. Sci. USA, 94, 9296-9301.
8. Chistiakov D. A. and Turakulov R. I. (2003): CTLA-4 and its role in autoimmune thyroid disease. J. Mol. Endocrinol., 31, 21-36.
9. Dariavach P., Mattei M. G., Golstein P. and Lefranc M. P. (1988): Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human cytoplasmic domains. Eur. J. Immunol., 18, 1901-1905.
10. Finger E. B. and Bluestone J. A (2002): When ligand becomes receptor- tolerance via B7 signaling on DCs. Nat. Immunol., 3, 1056-1057.
11. Giorelli M., Livera P., Defazio G., Ricchiuti F., Pagano E. and Trojano M. (2001): IFN-â1a modulates the expression of CTLA-4 and CD28 splice variants in human mononuclear cells: induction of soluble isoforms. J. Interferon Cytokine Res., 10, 809-812.
12. Grohmann U., Orabona C., Fallarino F., Vacca C., Calcinaro F., Falorni A., Candeloro P., Belladonna M. L., Bianchi R., Fioretti M. C. and Puccettt P. (2002): CTLA-4-Ig regulates catabolism in vivo. Nat. Immunol., 3, 1097-1101.
13. Harbo H. F., Celius E. G., Vartdal F. and Spurkland A. (1999): CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens, 53, 106-110
14. Harper K., Balzano C., Rouvier E., Mattei M. G., Luciani M. F. and Golstein P. (1991): CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal localization. J. Immunol., 147, 1037-1044.
15. Hathcock K. S., Laszlo G., Didder H. B., Bradshow J., Linsley P. and Hodes R. J. (1993): Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science, 262, 905-907.
16. Kaufman K. A., Bowen J. A., Tsai A. F., Bluestone J. A., Hunt J. S. and Ober C. (1999): The CTLA-4 gene is expressed in placental fibroblasts. Mol. Hum. Reprod., 5, 84-87.
17. Kosmaczewska A., Ciszak L., Bocko D. and Frydecka I. (2001): Expression and functional significance of CTLA-4, a negative regulator of T cell activation. Arch. Immunol. Ther. Exp., 49, 39-46.
18. Kuiper H. M., Brower M., Linsley P. S. and van Lier R. A. (1995): Activated T cells can induce high levels of CTLA-4 expression on B cells. J. Immunol., 155, 1776-1783.
19. Lafage-Pochitaloff M., Costello R., Couez D., Simonetti J., Mannoni P., Mawas C. and Olive D. (1990): Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33-q34. Immunogenetics, 31, 198-201.
20. Lanier L., O'Fallon S., Somoza C., Philips J. H., Linsley P. S., Okumura K., Ito D. and Azuma M. (1995): CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production and generation of CTL. J. Immunol., 154, 97-105.
21. Lee K. M., Chuang E., Griffin M., Khattri R., Hong D. K., Zhang W., Straus D., Samelson L. E., Thompson C. B. and Bluestone J. A. (1998): Molecular basis of T cell inactivation by CTLA-4. Science, 282, 2263-2266.
22. Ligers A., Xu C., Saarinen S., Hillert J. and Olerup O. (1999): The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol., 97, 182-190.
23. Lindsten T., Lee K. P., Harris E. S., Petryniak B., Craighead N., Reynolds P. J., Lombard D. B., Freeman G. J., Nadler L. M., Gray G. S., Thompson C. B. and June C. H. (1993): Characterization of CTLA-4 structure and expression on human T cells. J. Immunol., 151, 3489-3499.
24. Linsley P. S., Brady W., Urnes M., Grosmaire L., Aruffo A., Damle N. K. and Ledbetter J. A. (1991): Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med., 173, 561-569.
25. Linsley P. S., Greene J. L., Brady W., Bajorath J., Ledbeter J. A. and Peach R. (1994): Human B.7-1 (CD80) and B.7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity, 1, 793-801.
26. Linsley P. S., Greene J. L., Tan P., Bradschaw J., Ledbeter J. A., Anasetti C. and Damle N. K. (1992): Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocyte. J. Exp. Med., 176, 1595-1604.
27. Liu M. F., Wang C. R., Chen P. C. and Fung L. L. (2003): Increased of expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand. J. Immunol., 57, 568-572.
28. Magistrelli G., Jeannin P., Herbault N., De Coignac A. B., Gauchat J. F., Bonnefoy J. Y. and Delneste Y. (1999): A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol., 29, 3596-3602.
29. Mellor A. L. and Munn D. H. (1999): Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol. Today 20, 469-473.
30. Monoussakis M. N., Dimitriou I. D., Kapsogeorgou E. K., Xanthou G., Paikos S., Polichronis M. and Moutsopoulos H. M. (1999): Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjögren's syndrome. Arthritis Rheum., 42, 229-239.
31. Nagaraju K., Raben N., Villalba M. L., Danning C., Loeffler L. A., Lee E., Tresser N., Abati A., Fetsch P. and Plotz P. H. (1999): Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin. Immunol., 92, 161-169.
32. Oaks M. K. and Hallett K. M. (2000): Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J. Immunol., 164, 5015-5018.
33. Oaks M. K. Hallett K. M., Penwell R. T., Stauber E. C., Warren S. J. and Tector A. J. (2000): A native soluble form of CTLA-4. Cell. Immunol., 201, 144-153.
34. Oosterhuis H. J. (1964): Studies in myasthenia gravis: part 1. A clinical study of 180 patients. J. Neurol. Sci., 38, 512-546.
35. Oosterwegel M. A., Greenwald R. J., Mandelbrot D. A., Lorsbach R. B. and Sharpe A. H. (1999): CTLA-4 and T cell activation. Curr. Opin. Immunol., 11, 294-300.
36. Orozco G., Torres B., Nunez-Roldan A., Gonzalez-Escribano M. F. and Martin J. (2004): Cytotoxic T-lymphocyte antigen-4-CT60 polymorphism in rheumatoid arthritis. Tissue Antigens, 64, 667-670.
37. Peach R. J., Bajorath J., Brady W., Leytze G., Greene J., Naemura J. and Linsley P. S. (1994): Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine binding to B.7-1. J. Exp. Med., 180, 2049-2058.
38. Perez V. L., Van Parijs L., Biuckians A., Zheng X. X., Strom T. B. and Abbas A. K. (1997): Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity, 6, 411-417.
39. Perkins D., Wang Z., Donovan C., He H., Mark D., Guang G., Wang Y., Walunas T., Bluestone J., Listman J. and Finn P. W. (1996): Regulation of CTLA-4 expression during T cell activation. J. Immunol., 156, 4154-4159.
40. Saito T. (1998): Negative regulation of T cell activation. Curr. Opin. Immunol., 10, 313-321.
41. Sato S., Fujimoto M., Hasegawa M., Komura K., Yanaba K., Hayakawa I., Matsushita T. and Takehara K. (2004): Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology, 43, 1261-1266.
42. Shapiro V. S., Truitt K. E., Imboden J. B. and Weiss A. (1997): CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites. Mol. Cell. Biol., 17, 4051-4058.
43. Tivol E. A., Borriello F., Schweitzer A. N., Lynch W. P., Bluestone J. A. and Sharpe A. H. (1995): Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 3, 541-547.
44. Ueda H., Howson J. M., Esposito L., Heward J., Snook H., Chamberlain G., Rainbow D. B., Hunter K. M., Smith A. N., Di Genova G., Herr M. H., Dahlman I., Payne F., Smyth D., Lowe C. H., Twells R. C. J., Howlett S., Healy B., Nutland S., Ranee H. E., Everett V., Smink L. J., Lam A. C., Cordell H. J., Walker N. M., Bordin C., Hulme J., Motzo C., Cucca F., Hess J. F., Metzker M. L., Rogers J., Gregory S., Allahabadia A., Nitiyananthan R., Tuomilehto-Wolf E., Trigoviste C., Savage D. A., Maxwell A. P., Carson D. J., Patterson C. C., Franklyn J. A., Clayton D. G., Peterson L. B., Wicker L. S., Todd J. A. and Gough S. C. (2003): Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature, 423, 506-511.
45. Walunas T. L., Lenschow D. J., Bakker C. Y., Linsley P. S., Freeman G. J., Green J. M., Thompson C. B. and Bluestone J. A. (1994): CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1, 405-413.
46. Wang X. B., Giscombe R., Yan Z., Heiden T., Xu D. and Lefvert A. K. (2002): Expression of CTLA-4 by human monocytes. Scand. J. Immunol., 55, 53-60.
47. Wang X. B., Kakuolidou M., Giscombe R., Qiu Q., Huang D. R., Pirskanen R. and Lefvert A. K. (2002): Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J. Neurimmunol., 130, 224-232.
48. Waterhouse P., Penninger J. M., Timms E., Wakeham A., Shahinian A., Lee K. P., Thompson C. B., Griesser H. and Mak T. W. (1995): Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science, 270, 985-988.
49. Xerri L., Devilard E., Hassoun J., Olive D. and Brig F. (1997): In vivo expression of the CTLA-4 inhibitory receptor in malignant and reactive cells from human lymphomas. J. Pathol., 183, 182-187.